Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Total Debt (2022 - 2025)

Historic Total Debt for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $797275.0.

  • 60 Degrees Pharmaceuticals' Total Debt rose 2781.72% to $797275.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $797275.0, marking a year-over-year increase of 2781.72%. This contributed to the annual value of $640830.0 for FY2024, which is 7221.99% down from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Total Debt of $797275.0 as of Q3 2025, which was up 2781.72% from $776172.0 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Total Debt's 5-year high stood at $24.8 million during Q2 2023, with a 5-year trough of $565949.0 in Q1 2024.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Total Debt value was $776172.0 (recorded in 2025), while the average stood at $3.3 million.
  • Its Total Debt has fluctuated over the past 5 years, first crashed by 9770.98% in 2024, then soared by 3687.89% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Total Debt stood at $2.6 million in 2022, then decreased by 11.41% to $2.3 million in 2023, then plummeted by 72.22% to $640830.0 in 2024, then grew by 24.41% to $797275.0 in 2025.
  • Its Total Debt stands at $797275.0 for Q3 2025, versus $776172.0 for Q2 2025 and $635725.0 for Q1 2025.